Gerresheimer, a solutions provider for the pharma and biotech industries, will be presenting its prefillable syringe systems for ophthalmic applications at CPHI Worldwide 2024.
The silicone oil-free are made of glass or plastic, and ensure compatibility for sensitive ophthalmic drugs, while also offering precise dosing capabilities.
Avoiding silicone oil reduces the particle load, as well as the side effects associated with this ingredient.
The prefilled syringe will be delivered sterile to clients, removing the necessity of pretreatment.
The syringe systems have also received a silver award in the Drug Delivery Innovation category of the CPHI China Pharma Award.
“Syringes for ophthalmic injections must meet high standards in terms of compatibility, functionality and quality,” explains Stefan Verheyden, Global Vice President Biological Solutions and Syringes.
“Our new syringe systems are suitable for a wide range of ophthalmic medications, allow precise injection of small volumes and have a low particle load due to the absence of silicone oil. This minimises medical risks during treatment.”
Keeping up with eye disease technology
According to the World Health Organization (WHO), approximately 8 million people globally suffer from macular degeneration — an age-related retinal disease where central vision is partially or completely lost.
Therefore, there is a significant need for high compatibility, quality drug delivery devices for the treatment of such conditions.
Intravitreal injections and the special nature of ophthalmic drugs place high demands on the primary packaging of the drug and its administration.
The Gx RTF syringes meet these requirements for high compatibility, functionality and quality to a particularly high degree, including requirements for drugs based on the latest technology.
For chronic eye diseases, they have proven to be a superior option to the combination of injection vials and disposable draw-up syringes due to their highly precise dosage and user-friendly handling. They are especially preferred for the administration of antineovascular agents.
